Johnson & Johnson (NYSE:JNJ) Shares Acquired by Larson Financial Group LLC

Larson Financial Group LLC boosted its holdings in Johnson & Johnson (NYSE:JNJ) by 24.2% during the 3rd quarter, Holdings Channel.com reports. The fund owned 20,198 shares of the company’s stock after purchasing an additional 3,932 shares during the quarter. Larson Financial Group LLC’s holdings in Johnson & Johnson were worth $3,273,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. Managed Asset Portfolios LLC lifted its stake in Johnson & Johnson by 2.4% during the third quarter. Managed Asset Portfolios LLC now owns 167,332 shares of the company’s stock valued at $27,118,000 after buying an additional 3,866 shares in the last quarter. Sompo Asset Management Co. Ltd. raised its holdings in shares of Johnson & Johnson by 6.5% during the third quarter. Sompo Asset Management Co. Ltd. now owns 65,516 shares of the company’s stock valued at $10,618,000 after acquiring an additional 4,010 shares during the period. Wescott Financial Advisory Group LLC lifted its position in shares of Johnson & Johnson by 22.4% in the 3rd quarter. Wescott Financial Advisory Group LLC now owns 20,358 shares of the company’s stock valued at $3,299,000 after acquiring an additional 3,721 shares in the last quarter. Lane & Associates LLC boosted its stake in Johnson & Johnson by 8.8% in the 3rd quarter. Lane & Associates LLC now owns 4,627 shares of the company’s stock worth $750,000 after purchasing an additional 376 shares during the period. Finally, Truepoint Inc. grew its position in Johnson & Johnson by 26.9% during the 3rd quarter. Truepoint Inc. now owns 4,899 shares of the company’s stock worth $794,000 after purchasing an additional 1,038 shares in the last quarter. 69.55% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, VP Robert J. Decker sold 5,635 shares of the business’s stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $165.06, for a total transaction of $930,113.10. Following the transaction, the vice president now directly owns 18,973 shares of the company’s stock, valued at approximately $3,131,683.38. The trade was a 22.90 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.16% of the stock is owned by insiders.

Wall Street Analyst Weigh In

JNJ has been the subject of several research analyst reports. Wells Fargo & Company increased their price objective on Johnson & Johnson from $163.00 to $166.00 and gave the stock an “equal weight” rating in a research note on Wednesday, October 16th. Guggenheim raised their price target on shares of Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. StockNews.com upgraded shares of Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research note on Saturday, September 14th. Royal Bank of Canada lifted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $215.00 price target on shares of Johnson & Johnson in a research note on Wednesday, October 16th. Seven equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $175.94.

Johnson & Johnson Price Performance

Shares of JNJ opened at $155.17 on Friday. The company has a current ratio of 1.03, a quick ratio of 0.79 and a debt-to-equity ratio of 0.45. The stock has a market cap of $373.59 billion, a P/E ratio of 22.46, a price-to-earnings-growth ratio of 2.76 and a beta of 0.53. The stock’s 50-day moving average price is $160.21 and its two-hundred day moving average price is $156.26. Johnson & Johnson has a 1 year low of $143.13 and a 1 year high of $168.85.

Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings data on Tuesday, October 15th. The company reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.21 by $0.21. The company had revenue of $22.47 billion for the quarter, compared to the consensus estimate of $22.17 billion. Johnson & Johnson had a net margin of 19.14% and a return on equity of 35.45%. The firm’s revenue was up 5.2% compared to the same quarter last year. During the same period last year, the company earned $2.66 earnings per share. On average, equities analysts predict that Johnson & Johnson will post 9.93 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Stockholders of record on Tuesday, November 26th will be paid a dividend of $1.24 per share. The ex-dividend date is Tuesday, November 26th. This represents a $4.96 annualized dividend and a dividend yield of 3.20%. Johnson & Johnson’s dividend payout ratio is presently 71.78%.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.